Caronic anhydride (CAS NO.67911-21-1) is an intermediate for pharmaceuticals as Boceprevir and Paxlovid（nirmatrelvir and ritonavir）.
CAS No: 67911-21-1
Chemical name: 6,6-Dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione
|Appearance||Off-white to white crystalline solid||Off-white crystalline solid|
|Residue on ignition||NML 0.5%||0.1%|
The molecular structure of Boceprevir consists of three fragments: P1, P2 and P3.
Factory Price Caronic Anhydride for Sale
Pfizer's COVID-19 oral drug, Paxlovid, the main active ingredient Nirmatrelvir as follows has a molecular structure that also includes fragment P2.
Caronic anhydride is the raw material for the synthesis of fragment P2. Here, fragment P2 can be referred to as the registered starting material and Caronic anhydride can be referred to as the raw material.
PAXLOVID is an investigational medicine used to treat mild-to-moderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID is investigational because it is still being studied. There is limited information about the safety and effectiveness of using PAXLOVID to treat people with mild-to-moderate COVID-19. The FDA has authorized the emergency use of PAXLOVID for the treatment of mild-tomoderate COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with a positive test for the virus that causes COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, under an EUA.
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor, and ritonavir is an HIV-1 protease inhibitor and CYP3A inhibitor. Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing polyprotein precursors, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay with a Ki value of 3.1 nM and an IC50 value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography. Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.
Request a Quote